Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).

被引：0
|
作者：
Apolo, Andrea Borghese
Lee, Young H.
Cecchi, Fabiola
Agarwal, Piyush K.
Parnes, Howard L.
Khadar, Kattie
Summerell, Amelia
Gulley, James L.
Compton, Kathryn
Figg, William Douglas
Dahut, William L.
Bottaro, Donald P.
机构：
[1] NCI, Bethesda, MD 20892 USA
[2] NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA
[3] NCI, Canc Prevent Div, Bethesda, MD 20892 USA
[4] NCI, Med Oncol Branch, Bethesda, MD 20892 USA
[5] NCI, Mol Pharmacol Sect, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4543
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT)
    Winer, Eric P.
    Tolaney, Sara
    Nechushtan, Hovav
    Berger, Raanan
    Kurzrock, Razelle
    Ron, Ilan-Gil
    Schoffski, Patrick
    Awada, Ahmad
    Yasenchak, Christopher A.
    Burris, Howard A.
    Ramies, David A.
    Rafferty, Teresa
    Shen, Xiaodong
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT)
    Gordon, Michael S.
    Kluger, Harriet M.
    Shapiro, Geoffrey
    Kurzrock, Razelle
    Edelman, Gerald
    Samuel, Thomas A.
    Moussa, Ali H.
    Ramies, David A.
    Laird, A. Douglas
    Schimmoller, Frauke
    Shen, Xiaodong
    Daud, Adil
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] Phase II study of XL184 (cabozantinib) in recurrent or metastatic endometrial cancer: A trial or the PMH, Chicago, and California Phase II Consortia
    Wilson, Michelle
    Dhani, Neesha C.
    Hirte, Hai W.
    Welch, Stephen
    Steed, Helen
    Martin, Lalnie P.
    Lheureux, Stephanie
    Martin-Lorente, Cristina
    Mackay, Helen
    Butler, Marcus O.
    Wang, Lisa
    Quintos, Judy
    Allen, Katie
    Roman, Lynda
    Wright, John Joseph
    Oza, Amit M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT).
    Hellerstedt, Beth A.
    Edelman, Gerald
    Vogelzang, Nicholas J.
    Kluger, Harriet M.
    Yasenchak, Christopher A.
    Shen, Xiaodong
    Ramies, David A.
    Gordon, Michael S.
    Lara, Primo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer
    Choudhury, Atish D.
    Gray, Kathryn P.
    Supko, Jeffrey G.
    Harshman, Lauren C.
    Taplin, Mary-Ellen
    Pace, Amanda F.
    Farina, Matthew
    Zukotynski, Katherine A.
    Bernard, Brandon
    Kantoff, Philip W.
    Pomerantz, Mark
    Sweeney, Christopher
    PROSTATE, 2018, 78 (14): : 1053 - 1062
  • [26] Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT)
    Verslype, Chris
    Cohn, Allen Lee
    Kelley, Robin Katie
    Yang, Tsai-Shen
    Su, Wu-Chou
    Ramies, David A.
    Lee, Yihua
    Shen, Xiaodong
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT).
    Buckanovich, R. J.
    Berger, R.
    Sella, A.
    Sikic, B. I.
    Shen, X.
    Ramies, D. A.
    Smith, D. C.
    Vergote, I. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [28] Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.
    Hussain, M.
    Smith, M. R.
    Sweeney, C.
    Corn, P. G.
    Elfiky, A.
    Gordon, M. S.
    Haas, N. B.
    Harzstark, A. L.
    Kurzrock, R.
    Lara, P.
    Lin, C.
    Sella, A.
    Small, E. J.
    Spira, A. I.
    Vaishampayan, U. N.
    Vogelzang, N. J.
    Scheffold, C.
    Ballinger, M. D.
    Schimmoller, F.
    Smith, D. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
    Yakes, F. Michael
    Chen, Jason
    Tan, Jenny
    Yamaguchi, Kyoko
    Shi, Yongchang
    Yu, Peiwen
    Qian, Fawn
    Chu, Felix
    Bentzien, Frauke
    Cancilla, Belinda
    Orf, Jessica
    You, Andrew
    Laird, A. Douglas
    Engst, Stefan
    Lee, Lillian
    Lesch, Justin
    Chou, Yu-Chien
    Joly, Alison H.
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (12) : 2298 - 2308
  • [30] Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT)
    Cohn, Allen Lee
    Kelley, Robin Katie
    Yang, Tsai-Shen
    Su, Wu-Chou
    Verslype, Chris
    Ramies, David A.
    Lee, Yihua
    Shen, Xiaodong
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
12345